Home/Filings/4/0000950170-25-045283
4//SEC Filing

Kastelein Johannes Jacob Pieter 4

Accession 0000950170-25-045283

CIK 0001936258other

Filed

Mar 25, 8:00 PM ET

Accepted

Mar 26, 4:27 PM ET

Size

8.5 KB

Accession

0000950170-25-045283

Insider Transaction Report

Form 4
Period: 2025-03-24
Kastelein Johannes Jacob Pieter
DirectorChief Scientific Officer
Transactions
  • Exercise/Conversion

    Option (right to buy)

    2025-03-24150,000820,229 total(indirect: See footnote)
    Exp: 2031-07-06Ordinary Shares (150,000 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2025-03-24+150,000150,000 total(indirect: See footnote)
Footnotes (4)
  • [F1]The exercise price of the option is 1.16392 Euros.
  • [F2]The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.
  • [F3]The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
  • [F4]The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the issuer.

Documents

1 file

Issuer

NewAmsterdam Pharma Co N.V.

CIK 0001936258

Entity typeother

Related Parties

1
  • filerCIK 0002000389

Filing Metadata

Form type
4
Filed
Mar 25, 8:00 PM ET
Accepted
Mar 26, 4:27 PM ET
Size
8.5 KB